OpenURL Connection Search

Select item for more details and to access through your institution.

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
Published in:
Infectious Diseases & Therapy, 2024, v. 13, n. 3, p. 521, doi. 10.1007/s40121-024-00931-4
By:
- Hobbs, F. D. Richard;
- Montgomery, Hugh;
- Padilla, Francisco;
- Simón-Campos, Jesus Abraham;
- Arbetter, Douglas;
- Seegobin, Seth;
- Kiazand, Alexandre;
- Streicher, Katie;
- Martinez-Alier, Nuria;
- Cohen, Taylor S.;
- Esser, Mark T.
Publication type:
Article
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Published in:
Infectious Diseases & Therapy, 2023, v. 12, n. 12, p. 2691, doi. 10.1007/s40121-023-00882-2
By:
- Kijak, Gustavo H.;
- Ahani, Bahar;
- Arbetter, Douglas;
- Chuecos, Fernando;
- Gopalakrishnan, Vancheswaran;
- Beloor, Jagadish;
- Brady, Tyler;
- Nguyen, Amy;
- Roe, Tiffany L.;
- Schuko, Nicolette;
- Zhang, Tianhui;
- Hobbs, F. D. Richard;
- Padilla, Francisco;
- Kelly, Elizabeth J.;
- Montgomery, Hugh;
- Streicher, Katie
Publication type:
Article
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Published in:
Infectious Diseases & Therapy, 2023, v. 12, n. 9, p. 2269, doi. 10.1007/s40121-023-00861-7
By:
- Hobbs, F. D. Richard;
- Montgomery, Hugh;
- Padilla, Francisco;
- Simón-Campos, Jesus Abraham;
- Kim, Kenneth;
- Arbetter, Douglas;
- Padilla, Kelly W.;
- Reddy, Venkatesh Pilla;
- Seegobin, Seth;
- Streicher, Katie;
- Templeton, Alison;
- Viani, Rolando M.;
- Johnsson, Eva;
- Koh, Gavin C. K. W.;
- Esser, Mark T.
Publication type:
Article
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Published in:
Pharmaceutical Statistics, 2017, v. 16, n. 6, p. 445, doi. 10.1002/pst.1823
By:
- Arbetter, Douglas F.;
- Jain, Purva;
- Yee, Megan K.;
- Michalak, Nathan;
- Hernandez, Adrian F.;
- Hull, Russell D.;
- Goldhaber, Samuel Z.;
- Harrington, Robert A.;
- Gold, Alex;
- Cohen, Alexander T.;
- Gibson, C. Michael
Publication type:
Article
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Published in:
Journal of the American Heart Association, 2017, v. 6, n. 7, p. 1, doi. 10.1161/JAHA.117.006015
By:
- Gibson, C. Michael;
- Korjian, Serge;
- Chi, Gerald;
- Daaboul, Yazan;
- Jain, Purva;
- Arbetter, Douglas;
- Goldhaber, Samuel Z.;
- Hull, Russel;
- Hernandez, Adrian F.;
- Lopes, Renato D.;
- Gold, Alex;
- Cohen, Alexander T.;
- Harrington, Robert A.
Publication type:
Article

Found: 5

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.

Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.